ACCOUNTS - Final Accounts


Caseware UK (AP4) 2019.0.227 2019.0.227 2019-09-302019-09-3020638102632018-10-01falseThe principal activity of the company during the year was that of Research & Development in pharmaceutical sciences.truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 07373043 2018-10-01 2019-09-30 07373043 2019-09-30 07373043 2018-09-30 07373043 c:Director2 2018-10-01 2019-09-30 07373043 d:OfficeEquipment 2018-10-01 2019-09-30 07373043 d:OfficeEquipment 2019-09-30 07373043 d:OfficeEquipment 2018-09-30 07373043 d:OfficeEquipment d:OwnedOrFreeholdAssets 2018-10-01 2019-09-30 07373043 d:CurrentFinancialInstruments 2019-09-30 07373043 d:CurrentFinancialInstruments 2018-09-30 07373043 d:CurrentFinancialInstruments d:WithinOneYear 2019-09-30 07373043 d:CurrentFinancialInstruments d:WithinOneYear 2018-09-30 07373043 d:ShareCapital 2019-09-30 07373043 d:ShareCapital 2018-09-30 07373043 d:SharePremium 2019-09-30 07373043 d:SharePremium 2018-09-30 07373043 d:RetainedEarningsAccumulatedLosses 2019-09-30 07373043 d:RetainedEarningsAccumulatedLosses 2018-09-30 07373043 c:FRS102 2018-10-01 2019-09-30 07373043 c:AuditExempt-NoAccountantsReport 2018-10-01 2019-09-30 07373043 c:FullAccounts 2018-10-01 2019-09-30 07373043 c:PrivateLimitedCompanyLtd 2018-10-01 2019-09-30 07373043 d:OtherGroupMember1 d:SettlementLiabilities 2018-10-01 2019-09-30 07373043 d:OtherGroupMember1 d:SettlementLiabilities 2017-10-01 2018-09-30 07373043 d:OtherGroupMember1 d:SettlementLiabilities 2019-09-30 07373043 d:OtherGroupMember1 d:SettlementLiabilities 2018-09-30 07373043 d:OtherGroupMember2 d:SettlementLiabilities 2018-10-01 2019-09-30 07373043 d:OtherGroupMember2 d:SettlementLiabilities 2017-10-01 2018-09-30 iso4217:GBP
Registered number: 07373043


NANOMERICS LTD
UNAUDITED
FINANCIAL STATEMENTS
INFORMATION FOR FILING WITH THE REGISTRAR
FOR THE YEAR ENDED 30 SEPTEMBER 2019

 
NANOMERICS LTD
REGISTERED NUMBER:07373043

BALANCE SHEET
AS AT 30 SEPTEMBER 2019

2019
2018
Note
£
£

Fixed assets
  

Tangible assets
 4 
-
1,198

  
-
1,198

Current assets
  

Debtors: amounts falling due within one year
 5 
40,631
80,565

Cash at bank and in hand
 6 
50,105
67,068

  
90,736
147,633

Creditors: amounts falling due within one year
 7 
(35,143)
(74,760)

Net current assets
  
 
 
55,593
 
 
72,873

Total assets less current liabilities
  
55,593
74,071

  

Net assets
  
55,593
74,071


Capital and reserves
  

Called up share capital 
  
1,010
1,010

Share premium account
  
990
990

Profit and loss account
  
53,593
72,071

  
55,593
74,071


Page 1

 
NANOMERICS LTD
REGISTERED NUMBER:07373043
    
BALANCE SHEET (CONTINUED)
AS AT 30 SEPTEMBER 2019

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 


Dr A G Schatzlein
Director

Date: 28 August 2020

The notes on pages 3 to 8 form part of these financial statements.

Page 2

 
NANOMERICS LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2019

1.


General information

Nanomerics Limited is a private company, limited by shares, company registration number 07373043,  incorporated in England and Wales. The registered office is 6th Floor, 2 London Wall, London Wall Place, London, EC2Y 5AU.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The financial statements are prepared in pounds sterling, rounded to the nearest £1.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements have been prepared on a going concern basis, having considered relevant information, including the annual budget, forecast future cash flows and the potential impact of subsequent events, including the COVID-19 pandemic. The pandemic is considered to have limited material impact on trading over the course of the next twelve months and, in fact, brings additional opportunities for the business.
The analysis of forecast future cash flows, taking into account a number of scenarios, concludes that there is no material uncertainty and that the business can continue to adopt the going concern basis in preparing the director's report and accounts.

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 3

 
NANOMERICS LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2019

2.Accounting policies (continued)

 
2.4

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment
-
2 years straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of Comprehensive Income.

 
2.5

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.7

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in the case of an out-right short-term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each
Page 4

 
NANOMERICS LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2019

2.Accounting policies (continued)


2.7
Financial instruments (continued)

reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Comprehensive Income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

 
2.8

Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.9

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is pounds sterling, rounded to the nearest £1.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in the Statement of Comprehensive Income within 'other operating income'.

Page 5

 
NANOMERICS LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2019

2.Accounting policies (continued)

 
2.10

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

 
2.11

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in the Statement of Comprehensive Income when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.12

Taxation

Tax is recognised in the Statement of Comprehensive Income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

 
2.13

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.14

Grant income

Grant income is recognised by the company on a receivable basis and when the Company is entitled to receipt and is included in turnover. 

Exceptional items are transactions that fall within the ordinary activities of the Company but are presented separately due to their size or incidence.

Page 6

 
NANOMERICS LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2019

3.


Employees

The average monthly number of employees, including directors, during the year was 3 (2018 - 3).


4.


Tangible fixed assets





Office equipment

£



Cost or valuation


At 1 October 2018
4,609



At 30 September 2019

4,609



Depreciation


At 1 October 2018
3,411


Charge for the year on owned assets
1,198



At 30 September 2019

4,609



Net book value



At 30 September 2019
-



At 30 September 2018
1,198


5.


Debtors

2019
2018
£
£


Trade debtors
13
51,713

Other debtors
38,209
10,892

Prepayments and accrued income
2,409
17,960

40,631
80,565


Page 7

 
NANOMERICS LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2019

6.


Cash and cash equivalents

2019
2018
£
£

Cash at bank and in hand
50,105
67,068

50,105
67,068



7.


Creditors: Amounts falling due within one year

2019
2018
£
£

Trade creditors
24,769
32,087

Other taxation and social security
1,732
838

Other creditors
3,792
1,872

Accruals and deferred income
4,850
39,963

35,143
74,760



8.


Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £1,147 (2018: £1,749). Contributions totalling £540 (2018: £1,134) were payable to the fund at the balance sheet date and are included in other creditors.


9.


Transactions with directors

Following net loan movements in the year of £2,683 (2018 £1,780), at the balance sheet date included in other debtors due within one year is £1,717 (2018: £4,400) due from director Dr A G Schatzlein. This loan is unsecured, interest free and was repaid post year end. 

During the year dividends were paid to directors: a dividend of £10,000 (2018: £5,000) was paid to Dr A G Schatzlein, £10,000 (2018: £5,000)  paid to Dr I F Uchegbu and £638 (2018: £263) paid to Dr A Bye.

 
Page 8